Alexander Tremont1, Jonathan Lu2, John T Cole2,3. 1. Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA. 2. Department of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA. 3. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.
Abstract
BACKGROUND: Although breast cancer is still the second most common cause of cancer-related deaths, breast cancer mortality has been declining because of advances in the use of adjuvant therapies. METHODS: We summarize clinical trials involving endocrine therapies used to treat early breast cancer and discuss their inception and recent advances. RESULTS: Endocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality. Aromatase inhibitors such as anastrozole and letrozole have further improved breast cancer survival. CONCLUSION: With the implementation of such therapies resulting in decreased mortality, patients with breast cancer are living longer than ever before. The focus of research is now directed toward the length of treatment and prediction models for recurrence.
BACKGROUND: Although breast cancer is still the second most common cause of cancer-related deaths, breast cancer mortality has been declining because of advances in the use of adjuvant therapies. METHODS: We summarize clinical trials involving endocrine therapies used to treat early breast cancer and discuss their inception and recent advances. RESULTS: Endocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality. Aromatase inhibitors such as anastrozole and letrozole have further improved breast cancer survival. CONCLUSION: With the implementation of such therapies resulting in decreased mortality, patients with breast cancer are living longer than ever before. The focus of research is now directed toward the length of treatment and prediction models for recurrence.
Entities:
Keywords:
Aromatase inhibitors; breast cancer; estrogen receptor antagonists; tamoxifen
Authors: Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-01-02 Impact factor: 44.544
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Edith A Perez; Robert G Josse; Kathleen I Pritchard; James N Ingle; Silvana Martino; Brian P Findlay; Tamara N Shenkier; Richard G Tozer; Michael J Palmer; Lois E Shepherd; Shifang Liu; Dongsheng Tu; Paul E Goss Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch Journal: N Engl J Med Date: 2005-12-29 Impact factor: 91.245
Authors: R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan S Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley J Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per E Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde Journal: N Engl J Med Date: 2004-03-11 Impact factor: 91.245